nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

08.03.2018 | Original Article – Cancer Research

CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer

verfasst von: Soo Jung Lee, Sun-Young Jun, In Hee Lee, Byung Woog Kang, Su Yeon Park, Hye Jin Kim, Jun Seok Park, Gyu-Seog Choi, Ghilsuk Yoon, Jong Gwang Kim

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study attempted to reveal the prognostic impact of microsatellite instability-high (MSI-H) colon cancer with tumor-infiltrating immune cells (TIICs) and immune checkpoint protein expression, which are good candidates for immunotherapy.

Materials and methods

The study included 89 patients with MSI-H colon cancer who underwent curative surgery at Kyungpook National University Chilgok Hospital. The expression status of specific inhibitory receptors, such as CD274 (programmed death-ligand 1, PD-L1), PDCD1 (programmed cell death 1, PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), lymphocyte-activation gene 3 (LAG3), and indolamine 2′3′-dioxygenase 1 (IDO1), was retrospectively analyzed using immunohistochemistry (IHC).

Results

Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. Meanwhile, CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. During the median follow-up duration of 39 months, 14 (15.7%) patients experienced disease recurrence. Among the five immune checkpoint proteins, CD274, LAG3, and IDO1 expressions in TIICs were significantly associated with a better disease-free survival (DFS) in a univariate analysis (P = 0.028, 0.037, and 0.030 respectively). Moreover, co-expression of CD274, LAG3, and IDO1 in TIICs showed an even better survival for DFS (P = 0.010). In a multivariate survival analysis, CD274, LAG3, and IDO1 expressions in TIICs remained as independent prognostic factors for a better DFS.

Conclusion

CD274, LAG3, and IDO1 expressions in TIICs showed a better prognosis for patients with MSI-H colon cancer. Thus, the potential therapeutic implications of these immune checkpoint molecules should be further investigated.

Nur mit Berechtigung zugänglich

Aguiar PN Jr et al (2016) The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8:479–488. https://doi.org/10.2217/imt-2015-0002 CrossRefPubMed

Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220–5227. https://doi.org/10.1158/1078-0432.CCR-08-0133 CrossRefPubMed

Brandacher G et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144–1151. https://doi.org/10.1158/1078-0432.CCR-05-1966 CrossRefPubMed

deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH (2015) CD25 identifies a subset of CD4(+)FoxP3(−) TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res 3:245–253. https://doi.org/10.1158/2326-6066.CIR-14-0146 CrossRefPubMed

Devaud N, Gallinger S (2013) Chemotherapy of MMR-deficient colorectal. cancer Fam Cancer 12:301–306. https://doi.org/10.1007/s10689-013-9633-z CrossRefPubMed

Gubin MM et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577–581. https://doi.org/10.1038/nature13988 CrossRefPubMedPubMedCentral

He Y et al (2016) Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 107:1193–1197. https://doi.org/10.1111/cas.12986 CrossRefPubMedPubMedCentral

Herbst RS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentral

Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7:197–208. https://doi.org/10.1038/nrclinonc.2010.18 CrossRefPubMed

Hiraoka K et al (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275–280. https://doi.org/10.1038/sj.bjc.6602934 CrossRefPubMedPubMedCentral

Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M (2017) Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 30:278–285. https://doi.org/10.1038/modpathol.2016.185 CrossRefPubMed

Kim HR et al (2016a) PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 6:36956. https://doi.org/10.1038/srep36956 CrossRefPubMedPubMedCentral

Kim JH, Park HE, Cho NY, Lee HS, Kang GH (2016b) Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer 115:490–496. https://doi.org/10.1038/bjc.2016.211 CrossRefPubMedPubMedCentral

Le DT et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/NEJMoa1500596 CrossRefPubMedPubMedCentral

Lee KS et al (2017) Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother 66:927–939. https://doi.org/10.1007/s00262-017-1999-6 CrossRefPubMed

Li X, Li M, Lian Z, Zhu H, Kong L, Wang P, Yu J (2016) Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol 11:753–761. https://doi.org/10.1007/s11523-016-0451-8 CrossRefPubMed

Llosa NJ et al (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43–51. https://doi.org/10.1158/2159-8290.CD-14-0863 CrossRefPubMed

Masugi Y et al (2017) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 66:1463–1473. https://doi.org/10.1136/gutjnl-2016-311421 CrossRefPubMed

Ogawa M, Watanabe M, Hasegawa T, Ichihara K, Yoshida K, Yanaga K (2017) Expression of CXCR-4 and IDO in human colorectal cancer: an immunohistochemical approach. Mol Clin Oncol 6:701–704. https://doi.org/10.3892/mco.2017.1207 CrossRefPubMedPubMedCentral

Ogino S et al (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90–96. https://doi.org/10.1136/gut.2008.155473 CrossRefPubMed

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417–2422CrossRefPubMed

Soliman H, Mediavilla-Varela M, Antonia S (2010) Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 16:354–359. https://doi.org/10.1097/PPO.0b013e3181eb3343 CrossRefPubMed

Speeckaert R et al (2012) Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 48:2004–2011. https://doi.org/10.1016/j.ejca.2011.09.007 CrossRefPubMed

Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171:1393–1405CrossRefPubMed

Wang Q, Liu F, Liu L (2017) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore) 96:e6369. https://doi.org/10.1097/MD.0000000000006369 CrossRef

Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141:293–302. https://doi.org/10.1016/j.ygyno.2016.03.008 CrossRefPubMed

Xiao Y, Freeman GJ (2015) The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5:16–18. https://doi.org/10.1158/2159-8290.CD-14-1397 CrossRefPubMedPubMedCentral

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2016) Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 57:91–103. https://doi.org/10.1016/j.ejca.2015.12.033 CrossRefPubMed

Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ, Xie CM, Hu QG (2016) Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell. lung cancer Oncotarget 7:13765–13781. https://doi.org/10.18632/oncotarget.7282 PubMed

Zhao T, Li C, Wu Y, Li B, Zhang B (2017) Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS One 12:e0176822. https://doi.org/10.1371/journal.pone.0176822 CrossRefPubMedPubMedCentral

Titel: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer
verfasst von: Soo Jung Lee
Sun-Young Jun
In Hee Lee
Byung Woog Kang
Su Yeon Park
Hye Jin Kim
Jun Seok Park
Gyu-Seog Choi
Ghilsuk Yoon
Jong Gwang Kim
Publikationsdatum: 08.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2620-x

Springer Medizin

CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer